Arthritis

Antiarthritic agents

Development of Hypogammaglobulinemia in Rheumatoid Arthritis Patients on Rituximab Treatment Associated with Better Treatment Response

Research conducted at the Ankara University School of Medicine has investigated the frequency of hypogammaglobulinemia development in rheumatoid arthritis (RA) patients receiving rituximab treatment. The study retrospectively evaluated 165 RA patients who received at least two courses of rituximab with a six-month interval between 2010 and 2021. The results showed